City

Bethesda (2)

Chicago (1)

Lafayette (1)

Nashville (1)

Omaha (1)

Condition

Leukemia (3)

Lymphocytic (3)

Chronic (2)

B-Cell (1)

Hodgkin Disease (1)

Lymphoma (1)

Multiple Myeloma (1)

Non-Hodgkin's Lymphoma (1)

Overall Status

Completed (2)

Terminated (1)

Sign in for free

Phase

phase 1 (2)

phase 2 (1)

Sponsor

National Cancer Institute (NCI) (2)

Pharmacyclics LLC. (1)

Collaborator

Intervention

lmb-2 (1)

obinutuzumab (1)

pci-24781 (1)

rhil-15 (1)

Study Documents

Intervention Type

drug (3)

biological (1)

Funder Type

NIH (2)

Industry (1)

Study Type

Interventional (3)

lymphocytic

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Leukemia, Lymphocytic, Chronic Trial run by the NCI (rhIL-15, Obinutuzumab)

Terminated

Has Results

Leukemia
+3 more

rhIL-15
Obinutuzumab

Bethesda, Maryland

National Institutes of Health Clinical Center

Mar 11, 2022

Leukemia, Lymphocytic, Chronic Trial run by the NCI (LMB-2)

Completed

Has Results

Leukemia
+2 more

LMB-2

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Dec 27, 2017

Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease Trial in United States (PCI-24781)

Completed

Lymphoma
+5 more

PCI-24781

Chicago, Illinois
+4 more

Jun 17, 2013